German Pricing Mechanism Adds Weak Economies, Could Spell Trouble For EU Industry
This article was originally published in The Pink Sheet Daily
The decision by the German pharmaceutical arbitration committee to include countries such as Greece in a final pricing mechanism will cut German prices and may have a Europe-wide effect.
You may also be interested in...
Germany’s reimbursement watchdog IQWiG’s first cost-effectiveness analysis uses four antidepressants as test case and finds they are overpriced.
Following negotiations, AstraZeneca’s clot buster Brilique has been awarded a price that has pleased both the manufacturer and health insurers – but industry as a whole remains skeptical of the system.
Pricing and market access continue to be trends that plague big pharma, even as patent expirations and lagging new drug launches create harder circumstances for companies.